Buy or sell Biosplice Therapeutics stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Biosplice Therapeutics Stock

Tissue-Level Regeneration

Founded

2008

Notable Investors

Starling group

Headquarters

San Diego CA, US

Total Funding

$120M

About Biosplice Therapeutics Stock

Samumed is in the medical research and development for tissue-level regeneration. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine, and oncology. Samumed adopted a fresh operating philosophy from the beginning — one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health.

Investors

Funding History

February 2021$60.0M
March 2021$60.0M

Management

Chief Executive Officer

Samikoglu Cevdet

Chief Financial Officer

Horsley Erich

Press

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 290K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo